The kidney as a target organ in pharmaceutical research

Marco Prunotto, Giulio Gabbiani, Silvia Pomposiello, Gianmarco Ghiggeri, Solange Moll

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Kidney diseases are a major source of morbidity and mortality in humans. In developed countries, mortality owing to chronic kidney disease (CKD) terminating in end-stage renal failure is comparable with that associated with cancer. A full understanding of the mechanisms implicated in the progression of CKD is needed to achieve its prevention and to delay the need for support strategies based on dialysis and transplantation. Renal fibrosis is the unifying feature of progressive renal alterations. In this review, we discuss the current status of possible mechanisms, tools and targets in CKD. Pathophysiological compound identification, biomarker discovery and accurate selection of clinical validation criteria appear to be three key elements needed to develop a successful innovative pharmaceutical approach to treating kidney diseases.

Original languageEnglish
Pages (from-to)244-259
Number of pages16
JournalDrug Discovery Today
Volume16
Issue number5-6
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Chronic Renal Insufficiency
Kidney Diseases
Kidney
Mortality
Developed Countries
Chronic Kidney Failure
Dialysis
Fibrosis
Transplantation
Biomarkers
Morbidity
Pharmaceutical Preparations
Pharmaceutical Research
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

The kidney as a target organ in pharmaceutical research. / Prunotto, Marco; Gabbiani, Giulio; Pomposiello, Silvia; Ghiggeri, Gianmarco; Moll, Solange.

In: Drug Discovery Today, Vol. 16, No. 5-6, 03.2011, p. 244-259.

Research output: Contribution to journalArticle

Prunotto, M, Gabbiani, G, Pomposiello, S, Ghiggeri, G & Moll, S 2011, 'The kidney as a target organ in pharmaceutical research', Drug Discovery Today, vol. 16, no. 5-6, pp. 244-259. https://doi.org/10.1016/j.drudis.2010.11.011
Prunotto, Marco ; Gabbiani, Giulio ; Pomposiello, Silvia ; Ghiggeri, Gianmarco ; Moll, Solange. / The kidney as a target organ in pharmaceutical research. In: Drug Discovery Today. 2011 ; Vol. 16, No. 5-6. pp. 244-259.
@article{c530cc33ff7041998746d6cace396f64,
title = "The kidney as a target organ in pharmaceutical research",
abstract = "Kidney diseases are a major source of morbidity and mortality in humans. In developed countries, mortality owing to chronic kidney disease (CKD) terminating in end-stage renal failure is comparable with that associated with cancer. A full understanding of the mechanisms implicated in the progression of CKD is needed to achieve its prevention and to delay the need for support strategies based on dialysis and transplantation. Renal fibrosis is the unifying feature of progressive renal alterations. In this review, we discuss the current status of possible mechanisms, tools and targets in CKD. Pathophysiological compound identification, biomarker discovery and accurate selection of clinical validation criteria appear to be three key elements needed to develop a successful innovative pharmaceutical approach to treating kidney diseases.",
author = "Marco Prunotto and Giulio Gabbiani and Silvia Pomposiello and Gianmarco Ghiggeri and Solange Moll",
year = "2011",
month = "3",
doi = "10.1016/j.drudis.2010.11.011",
language = "English",
volume = "16",
pages = "244--259",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "5-6",

}

TY - JOUR

T1 - The kidney as a target organ in pharmaceutical research

AU - Prunotto, Marco

AU - Gabbiani, Giulio

AU - Pomposiello, Silvia

AU - Ghiggeri, Gianmarco

AU - Moll, Solange

PY - 2011/3

Y1 - 2011/3

N2 - Kidney diseases are a major source of morbidity and mortality in humans. In developed countries, mortality owing to chronic kidney disease (CKD) terminating in end-stage renal failure is comparable with that associated with cancer. A full understanding of the mechanisms implicated in the progression of CKD is needed to achieve its prevention and to delay the need for support strategies based on dialysis and transplantation. Renal fibrosis is the unifying feature of progressive renal alterations. In this review, we discuss the current status of possible mechanisms, tools and targets in CKD. Pathophysiological compound identification, biomarker discovery and accurate selection of clinical validation criteria appear to be three key elements needed to develop a successful innovative pharmaceutical approach to treating kidney diseases.

AB - Kidney diseases are a major source of morbidity and mortality in humans. In developed countries, mortality owing to chronic kidney disease (CKD) terminating in end-stage renal failure is comparable with that associated with cancer. A full understanding of the mechanisms implicated in the progression of CKD is needed to achieve its prevention and to delay the need for support strategies based on dialysis and transplantation. Renal fibrosis is the unifying feature of progressive renal alterations. In this review, we discuss the current status of possible mechanisms, tools and targets in CKD. Pathophysiological compound identification, biomarker discovery and accurate selection of clinical validation criteria appear to be three key elements needed to develop a successful innovative pharmaceutical approach to treating kidney diseases.

UR - http://www.scopus.com/inward/record.url?scp=79952451067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952451067&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2010.11.011

DO - 10.1016/j.drudis.2010.11.011

M3 - Article

C2 - 21129499

AN - SCOPUS:79952451067

VL - 16

SP - 244

EP - 259

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 5-6

ER -